| Literature DB >> 35268696 |
Monisha Prasad1, Selvaraj Jayaraman1, Mohamed Ahmed Eladl2, Mohamed El-Sherbiny3, Mosaab Abdella Ebrahim Abdelrahman3, Vishnu Priya Veeraraghavan1, Srinivasan Vengadassalapathy4, Vidhya Rekha Umapathy5, Shazia Fathima Jaffer Hussain6, Kalaiselvi Krishnamoorthy1, Durairaj Sekar7, Chella Perumal Palanisamy8, Surapaneni Krishna Mohan9, Ponnulakshmi Rajagopal10.
Abstract
Natural products in the form of functional foods have become increasingly popular due to their protective effects against life-threatening diseases, low risk of adverse effects, affordability, and accessibility. Plant components such as phytosterol, in particular, have drawn a lot of press recently due to a link between their consumption and a modest incidence of global problems, such as Type 2 Diabetes mellitus (T2DM), cancer, and cardiovascular disease. In the management of diet-related metabolic diseases, such as T2DM and cardiovascular disorders, these plant-based functional foods and nutritional supplements have unquestionably led the market in terms of cost-effectiveness, therapeutic efficacy, and safety. Diabetes mellitus is a metabolic disorder categoriszed by high blood sugar and insulin resistance, which influence major metabolic organs, such as the liver, adipose tissue, and skeletal muscle. These chronic hyperglycemia fallouts result in decreased glucose consumption by body cells, increased fat mobilisation from fat storage cells, and protein depletion in human tissues, keeping the tissues in a state of crisis. In addition, functional foods such as phytosterols improve the body's healing process from these crises by promoting a proper physiological metabolism and cellular activities. They are plant-derived steroid molecules having structure and function similar to cholesterol, which is found in vegetables, grains, nuts, olive oil, wood pulp, legumes, cereals, and leaves, and are abundant in nature, along with phytosterol derivatives. The most copious phytosterols seen in the human diet are sitosterol, stigmasterol, and campesterol, which can be found in free form, as fatty acid/cinnamic acid esters or as glycosides processed by pancreatic enzymes. Accumulating evidence reveals that phytosterols and diets enriched with them can control glucose and lipid metabolism, as well as insulin resistance. Despite this, few studies on the advantages of sterol control in diabetes care have been published. As a basis, the primary objective of this review is to convey extensive updated information on the possibility of managing diabetes and associated complications with sterol-rich foods in molecular aspects.Entities:
Keywords: cholesterol; diabetes mellitus; insulin resistance; obesity; phytosterols; therapeutic implications
Mesh:
Substances:
Year: 2022 PMID: 35268696 PMCID: PMC8911698 DOI: 10.3390/molecules27051595
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1(a) Structure of cholesterol, (b) structure of β-sitosterol (ethyl group represents in red line), (c) structure of stigmasterol (ethyl group and double bond represented by red line), and (d) structure of campesterol (methyl group represented by red line).
Studies on biological activity of phytosterol from plants or as compounds.
| S. No. | Phytosteroor Its Sources | Model | Type of Study | Biological Activity of Phytosterol | Implication | Reference |
|---|---|---|---|---|---|---|
| 1 | 0.4% stigmasterol and β-sitosterol in the diet | Mice fed a Western-style high-fat diet | In vivo | Antilipidemic activity | The study found that phytosterols were beneficial in preventing nonalcoholic fatty liver disease (NAFLD) caused by a high-fat Western diet (HFWD) (NAFLD). In this long-term (33-week) investigation, phytosterols, at a dose comparable to that advised for the alleviation of NAFLD, were predominantly related to the decreases in hepatic cholesterol, triglycerides with polyunsaturated fatty acids, and modifications of hepatic-free fatty acid. | [ |
| 2 | Dry leaves of | Six female Swiss mice weighing 25–30 g each | In vivo | Anti-inflammatory activity | In the chromatographic fractionation of the | [ |
| 3 | In silico | Breast cancer | The ADME (Adsorption, Distribution, Metabolism, Excretion) characteristics, pharmacokinetic features, drug-likeliness, and acute toxicity of the discovered phytosterols compounds are predicted by ethanolic extracts | [ | ||
| 4 | β-sitosterol | Male albino wistar rats | In vivo | Anti-inflammatory activity | In high fat diet- and sucrose-induced type-2 diabetic rats, β-sitosterol treatment normalises raised serum levels of proinflammatory cytokines, such as leptin, resistin, tumour necrosis factor-(TNF-α), and interleukin-6 (IL-6) and increases anti-inflammatory adipocytokines, such as adiponectin. In diabetic rats’ adipocytes, β-sitosterol lowers sterol regulatory element binding protein-1c (SREBP-1c) and increases Peroxisome Proliferator–Activated Receptor-γ (PPAR-γ) gene expression. In β-sitosterol-treated groups, c-Jun-N-terminal kinase-1 (JNK1), inhibitor of nuclear factor kappa-B kinase subunit beta (IKK), and nuclear factor kappa B (NF-kB) gene and protein expression were likewise considerably reduced. This study reveals that SIT prevents obesity-induced insulin resistance by reducing inflammatory events in the adipose tissue via inhibiting the IKK/NF-kB and c-Jun-N-terminal kinase (JNK) signalling pathways. | [ |
| 5 | β-sitosterol | Male albino wistar rats | In vivo | Antidiabetic activity | Treatment with β-sitosterol restored the altered levels of blood glucose, serum insulin, testosterone, lipid profile, oxidative stress indicators, antioxidant enzymes, insulin receptor (IR), and glucose transporter 4 (GLUT4) proteins in a high-fat diet and sucrose-induced diabetic rats. This research shows that β-sitosterol improves glycemic control in high-fat and sucrose-induced type-2 diabetic rats through activating IR and GLUT4. In addition, the results of in silico analysis match those of in vivo testing. | [ |
| 6 | β-sitosterol | Male albino wistar rats | In vivo | Antidiabetic activity | When compared to high-fat diet and sucrose induced type-2 diabetic rats, β-sitosterol increased the mRNA expression of IR and post-receptor insulin signalling molecules such as IRS-1, β-arrestin-2, Akt, AS160, and GLUT4, as well as the levels of IRS-1, p-IRS1-1Tyr632, Akt, p-AktSer473/Thr308, AS160, and p-AS160Thr642. In this study, in silico analysis revealed that β-sitosterol has a higher binding affinity for β-arrestin-2, c-Src, and IRS-1, as well as Akt proteins, and has been shown to reduce insulin resistance, as evidenced by in vivo data. According to the findings, β-sitosterol reduces the potential effects of a high-fat diet on adipose tissue. | [ |
| 7 | β-sitosterol | Male albino wistar rats | In vivo | Antidiabetic activity | In this study, high-fat diet and sucrose-induced diabetic rats showed reduced glucose and insulin tolerances, as well as insulin signalling molecules (IR and GLUT4) and glycogen levels. Serum insulin, lipid profile, LPO, H2O2, and OH* levels were shown to be higher in diabetic rats. The β-sitosterol therapy brought blood glucose, insulin, lipid profile, oxidative stress indicators, IR, and GLUT4 protein levels back to normal. This research suggests that IR and GLUT4 activation by β-sitosterol improves glycemic control in the gastrocnemius muscle of HFD-fed and sucrose-induced type 2 diabetic rats. | [ |
| 8 | In vitro | Neuroprotective properties | Compressed fluid technologies were used to produce phytosterol-rich extracts from | [ | ||
| 9 | Soybean oil contains stigmasterol | KK-Ay mice | In vivo | Anti-diabetic activity | In L6 cells, stigmasterol greatly boosted GLUT4 translocation and glucose absorption. Furthermore, this in vivo research revealed that after 4 weeks of stigmasterol therapy, the hyperglycemic phenotype of diabetic KK-Ay mice was dramatically relieved, with significantly lower fasting glucose, indicating a considerable hypoglycemic impact against T2DM. In this investigation, stigmasterol appeared to offer potential benefits in the treatment of type 2 diabetes, with the likely method of targeting the GLUT4 glucose transporter, including increased GLUT4 translocation and expression. | [ |
| 10 | Lophenol (Lo) and cycloartanol (Cy), minor phytosterols of | Zucker diabetic fatty (ZDF) rats | In vivo | Anti-diabetic activity | After 35 days of treatment, minor phytosterols from | [ |
| 11 | Nuts | Human study | In vivo | Anti-diabetic activity | Randomised controlled studies of type 2 diabetes patients corroborated the positive benefits of nuts on blood lipids, which were also found in non-diabetic people, but no change in A1C or other glycated proteins was identified in the trials. However, acute feeding studies have shown that nuts can lower postprandial glycemia when consumed with a carbohydrate (bread). Additionally, nut intake was related to lower postprandial oxidative stress. Nuts have a favourable nutritional profile, being abundant in monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA), as well as being good sources of vegetable protein. Nuts may so increase the diet’s overall nutritious quality. | [ |
Figure 2Molecular mechanism of action of insulin signalling under physiology and pathophysiological condition. Normal insulin signalling begins with insulin binding to the insulin receptor, then phosphorylation of the Tyr residue of IRS 1/2, and finally, activation of the PI3K and Akt enzymes (a). Activated Akt causes glucose translocation for oxidation by activating the GLUT4 transloaction proteins. In insulin resistance, instead of Tyr phosphorlation, serine residue phosphorlation after insulin binding to the insulin receptor leads to decreased activation of PI3K and Akt, resulting in decreased GLUTt4 translocation and glucose uptake. The red arrow indiactes IRS1/2 serine phosphorylation-mediated inhibition PI3K/Akt/AS160-mediated signalling that leads to insulin resistance due to various factors (b).
Figure 3Phytosterols metabolism towards the regulation of cholesterol absorption. When phytosterol-rich foods are consumed, they are processed by liver enzymes that are comparable to those used to break down choletserol. It will reach the enterocytes after digestion, where phytosterol metabolism differs from cholesterol metabolism. Because these phytosterols are poor substrates of acyl-coA cholesterol actytransferase, they are not esterified and remain in the free form within the cell. Finally, the ATP-driven transporter heterodimer ABCG5/8 excretes the bulk of the free plant sterols back into the interstinal lumen.
Figure 4Overall therapeutic action of phytosterol. Phytosterol resembles cholesterol, which has been proven to inhibit interstinal cholesterol absorbtion and elevates antioxidants, making it a more effective antidiabetic, hypolipidemic, and anti-inflammatory agent. In addition to these actions, active phytosterol regulates insulin resistance, glucose and lipid metabolism, insulin signalling, and obesity management.
Figure 5Schematic mechanism of plant sterols regulating insulin signalling and inflammation. The mechanism of action of phytosterol is illustrated in the figure based on the literature available. As phytosterol is a potent antidiabetic, it enhances insulin signalling molecules, such as IR, IRS 1/2, PI3K, Akt, and AS160, which promotes GLUT4 synthesis and glucose absorption. There is still a lack of research on the effects of phytosterols on the GLUT4 translocation pathway (denoted as ?). Phytosterol also suppresses inflammatory events by inhibiting the IKK/NF-kB and c-Jun-N-terminal kinase (JNK) signalling pathways. Plant sterol-facilitated activation is indicated by a green plus symbol. The red circle denotes phytosterol’s inhibitory effect on bothinsulin signalling and inflammation.